Yes, there is a blood test for prostate cancer, and it’s been in use for decades. The PSA test measures a protein called prostate-specific antigen that your prostate naturally produces. When prostate cancer is present, PSA levels in the blood typically rise, making this a useful screening tool. However, an elevated PSA doesn’t confirm cancer on its own, and newer blood tests are improving on its accuracy.
How the PSA Test Works
Your prostate gland produces PSA as part of its normal function of making the fluid portion of semen. A small amount of this protein leaks into the bloodstream, and a simple blood draw can measure how much is circulating. Higher levels can signal that something is going on with the prostate, whether that’s cancer, an infection, or simply an enlarged gland.
What counts as a “normal” PSA depends on your age. For men in their 40s and 50s, the median PSA is around 0.6 to 0.7 ng/mL, and anything above 2.5 ng/mL is generally considered elevated. For men in their 60s, the normal range shifts upward to between 1.0 and 1.5 ng/mL, with readings above 4.0 ng/mL flagged as abnormal. PSA naturally rises with age because the prostate grows over time, which is why a single cutoff number doesn’t work for all men.
The False Positive Problem
The biggest limitation of the PSA test is that elevated results frequently turn out to be something other than cancer. In one large cohort study, nearly 47% of elevated PSA results were false positives. The test’s positive predictive value was just 12.7%, meaning that out of every 100 men with a high PSA reading, roughly 13 actually had prostate cancer. The false positive rate was almost identical in men with symptoms (47.9%) and those without (46.6%).
Several benign conditions can push PSA levels up. An enlarged prostate, a urinary tract infection, or prostatitis (inflammation of the prostate) can all cause elevated readings. Even everyday activities matter. Ejaculation can temporarily raise PSA for up to 24 hours, and long-distance cycling, which puts pressure on the prostate, has a similar effect. If you take finasteride for an enlarged prostate or hair loss, your doctor will typically double your PSA result to get a comparable reading, since the medication artificially suppresses PSA levels.
On the other side, the false negative rate is low, around 2.8%, meaning the test rarely misses cancer entirely.
Newer Blood Tests That Improve Accuracy
Because standard PSA alone casts such a wide net, newer blood tests have been developed to help doctors better distinguish cancer from harmless conditions.
The Prostate Health Index (PHI) combines three different forms of PSA into a single score: total PSA, free PSA (the portion not bound to proteins), and a specific subtype called [-2]proPSA. When researchers compared these tools head to head, PHI outperformed both standard PSA and free PSA at identifying men who actually had cancer on biopsy. It was also better at predicting clinically significant, higher-grade cancers, the kind most likely to need treatment.
The 4Kscore test takes a similar approach, measuring four prostate-related proteins in the blood: total PSA, free PSA, intact PSA, and a protein called kallikrein 2. It’s validated to predict whether a biopsy would find significant cancer. The 4Kscore is currently the only protein biomarker test with FDA premarket approval for prostate cancer screening and detection.
Insurance coverage for these advanced tests varies. Some insurers still classify protein biomarker tests as investigational, though Medicare has local coverage frameworks that may apply depending on your situation. If your doctor recommends PHI or the 4Kscore, it’s worth checking coverage beforehand.
Liquid Biopsies: A Technology Still Developing
A newer category of blood test called a liquid biopsy looks for fragments of tumor DNA circulating in the bloodstream. For advanced prostate cancer, these tests are already in clinical use. The FDA-approved FoundationOne Liquid CDx, for example, analyzes changes across more than 300 genes from a blood sample and is recommended by the American Society of Clinical Oncology as an alternative to tissue biopsy when metastatic tumors are hard to access.
For early-stage, localized prostate cancer, liquid biopsies are far less reliable. Tumors that haven’t spread release very little DNA into the blood, often falling below what current testing platforms can detect. The match between what a liquid biopsy finds and what’s actually in the tumor improves dramatically as cancer advances, from roughly 50% agreement in localized disease to 80 to 90% in metastatic cancer. Some experimental approaches using DNA methylation patterns have shown striking accuracy in research settings (one study reported 98.9% accuracy distinguishing localized from metastatic disease), but these are not yet standard clinical tools for initial screening.
What Happens After an Abnormal Result
An elevated PSA on its own doesn’t mean you’ll immediately need a biopsy. The typical path starts with a repeat PSA test to confirm the result, sometimes after addressing factors that could have caused a temporary spike. If levels remain elevated, a referral to a urologist is the next step. Many urologists now order an MRI of the prostate before deciding on a biopsy, which helps identify suspicious areas and reduces unnecessary biopsies.
If a biopsy is recommended, the standard procedure uses ultrasound or MRI guidance to take small tissue samples from the prostate. The tissue is then graded to determine whether cancer is present and, if so, how aggressive it appears. Not all prostate cancers need immediate treatment. Low-grade cancers are often monitored through a strategy called active surveillance, which involves regular PSA tests, occasional imaging, and repeat biopsies only when needed.
Who Should Get Tested
Current guidelines from the U.S. Preventive Services Task Force recommend that men ages 55 to 69 make an individual decision about PSA screening after discussing the potential benefits and harms with their doctor. For men 70 and older, the task force recommends against routine screening because the risks of overdiagnosis and unnecessary treatment tend to outweigh the benefits at that age.
Men at higher risk, including Black men and those with a family history of prostate cancer, may benefit from starting the conversation earlier, sometimes in their 40s. A baseline PSA in your 40s can be particularly useful because it establishes your personal starting point. A man whose PSA is already above 1.0 ng/mL in his 40s carries a higher lifetime risk than one whose level is well below that, even though both readings would technically fall in the “normal” range.
Preparing for a PSA Test
If you’re scheduled for a PSA blood draw, a few simple steps can help ensure an accurate result. Avoid ejaculation for at least 24 hours beforehand. Skip any long bike rides in the days leading up to the test. Let your doctor know if you’re taking finasteride or if you’ve recently had a urinary tract infection or any procedure involving the prostate. If your result comes back borderline high, your doctor may recommend retesting before taking further action, since a single reading is only a snapshot.